Duska Therapeutics Sets Annual Meeting of Shareholders for June 27

LA JOLLA, Calif., April 15 /PRNewswire-FirstCall/ -- Duska Therapeutics,
Inc., (OTC Bulletin Board: DSKA), a biotechnology company developing medical
products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related
technologies, announced today that it has scheduled its 2008 Annual Meeting of
Shareholders for 10AM (Eastern) on June 27, 2008.
The Annual Meeting will be held at the law offices of Fish and Richardson,
Citigroup Center, 153 East 53rd Street, 52nd Floor, New York, NY 10022.
At the Annual Meeting, Duska shareholders will be asked to approve the
election of directors and the reappointment of Duska's independent auditors.
The voting record date for determination of shareholders entitled to vote at
the meeting has been set at the close of business on May 2, 2008. Dr. James
Kuo, Duska's Chairman and CEO, will be providing an update on the company's
drug development programs and answering any questions.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., based in La Jolla, California, is a
biotechnology company focused on the development of medical products related
to adenosine 5'-triphosphate (ATP) and P2 receptors (P2R). Duska owns or has
exclusive license rights to a number of proprietary products in various stages
of development. Additional information is available at
http://www.duskatherapeutics.com.
Forward-looking statements
This press release may contain forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended that
involve risks and uncertainties that could cause actual events or results to
differ materially from the events or results described in the forward-looking
statements. The forward-looking statements are based on current expectations,
estimates and projections made by management. Duska intends for the
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates," or variations of such words are
intended to identify such forward-looking statements. All statements in this
release regarding the future outlook related to Duska are forward-looking
statements, such as the characterization of Duska as an emerging biotechnology
company. The forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set forth or
implied by any forward-looking statements. Additional uncertainties and risks
are described in Duska's most recently filed SEC documents, such as its most
recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and
any current reports on Form 8-K filed since the date of the last Form 10-KSB.
Copies of these filings are available through the SEC website at
http://www.sec.gov. All forward-looking statements are based upon information
available to Duska on the date hereof. Duska undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise.
SOURCE Duska Therapeutics, Inc.

James S. Kuo, M.D., M.B.A., Chairman and CEO of Duska Therapeutics, Inc.,
+1-858-551-5700, fax, +1-858-551-5704, kuoj@duskascientific.com